Using Dose Titration to Resolve Injection Site Reactions on Zepbound (Tirzepatide)

Does slowing the dose increase help an injection site reaction?

The label gives one stated reason for the stepwise dose schedule: to reduce the risk of gastrointestinal adverse reactions [1]. It does not describe slowing, pausing or lowering the dose as a response to injection site reactions.

In the pooled weight-reduction trials, injection site reactions were more frequent on each active dose than on placebo: 6% at 5 mg, 8% at 10 mg and 8% at 15 mg, against 2% on placebo [1]. The label groups bruising, erythema, pruritus, pain, rash and injection site reaction under that single reporting term [1].

Dose changes the label describes

Zepbound starts at 2.5 mg once weekly for 4 weeks, then 5 mg, with further increases of 2.5 mg after at least 4 weeks on the current dose [1]. The 2.5 mg dose is for treatment initiation and is not approved as a maintenance dose [1]. Maintenance is 5 mg, 10 mg or 15 mg once weekly for weight reduction, and 10 mg or 15 mg for obstructive sleep apnea; 15 mg is the maximum for any indication [1].

The label says to consider treatment response and tolerability when selecting the maintenance dose, and that if patients do not tolerate a maintenance dose, a lower maintenance dose should be considered; that statement is general and is not specific to injection site reactions [1].

Where the label says to inject

The label says to inject in the abdomen, thigh or back of the upper arm and to rotate sites, with the upper arm injected by another person [1]. Tirzepatide exposure was similar at the abdomen, thigh and upper arm [1]. The label names three presentations — vial, prefilled single-dose pen and single-patient-use KwikPen — and says patients should be trained on the one they receive [1].

When a reaction is serious

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [1]. In the pooled weight-reduction trials, 0.1% of Zepbound-treated patients had severe hypersensitivity reactions, versus none on placebo [1]. The label says that if a hypersensitivity reaction occurs, patients should promptly seek medical attention and discontinue Zepbound [1]. Known serious hypersensitivity to tirzepatide or any excipient is a contraindication [1].